VectorBuilder Redefines Plasmid Standards with miniVec
Conventional plasmids as a pharmaceutical material are not only suboptimal in safety and function, but exceedingly costly to produce, prohibitively
Conventional plasmids as a pharmaceutical material are not only suboptimal in safety and function, but exceedingly costly to produce, prohibitively
Stephan brings more than 20 years of leadership experience in the pharmaceutical industry
Lonza boosts TheraPEAK line with new Cytokines and AAV Medium for next-gen therapies
Expanded capabilities that continue to push the boundaries of innovation—advancing drug delivery solutions for patients, customers, and consumers around the world
The association called for an end to the constant issuance of regulatory circulars that make operations unpredictable and capital-intensive.
Ultra-high purity surfactant for biologics and parenteral drug formulations
The FDA is beginning rulemaking to close the “adequate provision” loophole
Maria Soler Nunez appointed as Chief Quality Officer
Subscribe To Our Newsletter & Stay Updated